Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study

MLA

Rubén Martín-Escolano, et al. “Low Plasma Levels of BTLA and LAG-3 before HCV Therapy Are Associated with Metabolic Disorders after HCV Eradication in Persons with HIV/HCV Coinfection: A Retrospective Study.” Frontiers in Pharmacology, vol. 15, Oct. 2024. EBSCOhost, https://doi.org/10.3389/fphar.2024.1341612.

APA

Rubén Martín-Escolano, Ana Virseda-Berdices, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, Amanda Fernández-Rodríguez, Cristina Díez, Victor Hontañon, The Marathon Study Group, Salvador Resino, María Ángeles Jiménez-Sousa, A. Arranz, F. Arnalich, J. R. Arribas, E. Aznar, T. Aldamiz-Echevarría, J. Bermejo, J. Berenguer, J. M. Bellón, … J. F. Zamora. (2024). Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1341612

Chicago

Rubén Martín-Escolano, Ana Virseda-Berdices, Juan Berenguer, Juan González-García, Oscar Brochado-Kith, Amanda Fernández-Rodríguez, Cristina Díez, et al. 2024. “Low Plasma Levels of BTLA and LAG-3 before HCV Therapy Are Associated with Metabolic Disorders after HCV Eradication in Persons with HIV/HCV Coinfection: A Retrospective Study.” Frontiers in Pharmacology 15 (October). doi:10.3389/fphar.2024.1341612.